DNLI Biotechnology · Rare disease · Neuroscience · Commercial launch · Thesis updated July 1, 2026

Approved, but now Denali must sell

AVLAYAH won FDA accelerated approval in March 2026, moving Denali from a research story to a launch story.
The approval triggered $200 million in gross proceeds from Royalty Pharma and came with a rare pediatric disease priority review voucher.
The main question is no longer whether Denali can get its first drug approved, but whether patients, doctors, and insurers will use it.
Takeda's April 2026 exit from DNL593 adds to a pattern of partner pullbacks across the pipeline.
Pipeline readouts in Parkinson's disease, ulcerative colitis, FTD-GRN, and MPS IIIA could either widen the story or show the platform is still narrow.

01 Running thesis

The approval test is over

Denali cleared its biggest near-term hurdle. The FDA approved AVLAYAH, also called tividenofusp alfa, for neurologic signs of Hunter syndrome in March 2026. That moved the company into commercial biotech status and triggered $200 million in gross proceeds from Royalty Pharma.

The bull case is now about launch quality. If AVLAYAH gains coverage from insurers, reaches eligible children quickly, and earns doctor trust, it can fund more of Denali's pipeline. It would also give real-world proof for Denali's Transport Vehicle platform, which is meant to carry large drugs across the blood-brain barrier.

The bear case changed too. A poor launch would hurt confidence that Denali can shift from science to sales. AVLAYAH also has accelerated approval, which means the FDA can require proof of benefit in a confirmatory study. If that study fails, the product could be pulled.

The next year has several swing factors: AVLAYAH sales and payor coverage, a possible sale of the priority review voucher, the BIIB122 LUMA readout in Parkinson's disease, Sanofi's eclitasertib data in ulcerative colitis, DNL593 data after Takeda's exit, and completion of the DNL126 MPS IIIA study.

May 2026▲AVLAYAH received accelerated FDA approval, Denali received $200 million in gross proceeds from Royalty Pharma, and the FDA granted a priority review voucher. The positive shift is partly offset by Takeda's DNL593 termination.

Feb 2026▲Denali entered 2026 with an April 5 PDUFA date for tividenofusp alfa and a Royalty Pharma funding deal tied to approval. The D3X3 plan showed a clear push from platform validation toward commercial delivery.

Nov 2025→The FDA extended the tividenofusp alfa review timeline from January 5 to April 5, 2026 after asking for more clinical pharmacology information. The core setup stayed intact, but the decision moved later.

Aug 2025▲The FDA accepted the tividenofusp alfa BLA for priority review, giving Denali a January 5, 2026 target action date. Denali also aligned with the FDA on a surrogate endpoint that could support accelerated approval for DNL126.

May 2025▲Denali completed the rolling BLA submission for tividenofusp alfa. That moved the lead program from clinical proof toward FDA review and possible launch preparation.

Feb 2025▼The thesis became more concentrated in the ETV platform as DNL343 failed in ALS and several partnered programs were terminated. Tividenofusp alfa still offered a clear path to a BLA, but the rest of the pipeline looked riskier.

Nov 2024▲Denali said it planned to file for accelerated approval of tividenofusp alfa after a successful FDA meeting. This improved the near-term path for the lead Hunter syndrome program.

Aug 2024→The initial view framed Denali as a pre-commercial biotech built around blood-brain barrier delivery. The key risks were platform proof, clinical failure, and reliance on partners.

02 Business model

A platform with one launched drug

Denali's model starts with a hard problem: many drugs cannot cross the blood-brain barrier, the body's shield around the brain. Its Transport Vehicle platform is designed to carry enzymes, proteins, antibodies, and oligonucleotides into the brain after intravenous dosing.

The company now expects revenue from AVLAYAH product sales, along with collaboration revenue from partners. Before AVLAYAH, Denali said all revenue recognized to date came from collaboration and license agreements with partners such as Takeda, Sanofi, and Biogen.

Funding also comes from the Royalty Pharma synthetic royalty agreement. Royalty Pharma agreed to provide up to $275 million in funding in exchange for a 9.25% royalty on future net sales of tividenofusp alfa, and Denali received $200 million in gross proceeds after AVLAYAH approval.

The weak point is dependence. Denali needs a smooth rare disease launch, successful follow-up trials, and partner support for major programs. Takeda's DNL593 termination shows that partners can leave even after a drug reaches human testing.

03 Product portfolio

What Denali is trying to sell and prove

Growth engine

AVLAYAH, tividenofusp alfa-eknm

AVLAYAH is Denali's first approved product. It treats neurologic manifestations in Hunter syndrome and began commercial distribution in April 2026 after accelerated FDA approval.

Option

DNL126, ETV:SGSH

DNL126 is an enzyme therapy for Sanfilippo syndrome Type A, also called MPS IIIA. The Phase 1/2 study is fully enrolled, and Denali is targeting a possible accelerated approval path in the second half of 2027.

Option

BIIB122, DNL151

BIIB122 is a LRRK2 inhibitor for Parkinson's disease partnered with Biogen. Phase 2b LUMA data are expected in mid-2026.

Option

Eclitasertib, SAR443122/DNL758

Eclitasertib is a peripheral RIPK1 inhibitor for ulcerative colitis partnered with Sanofi. A Phase 2 data readout is expected in the first half of 2026.

Option

DNL593, PTV:PGRN

DNL593 is a progranulin therapy for frontotemporal dementia caused by GRN mutations. Takeda terminated the collaboration in April 2026, so full rights are set to return to Denali.

Option

DNL952, ETV:GAA

DNL952 is an enzyme therapy for Pompe disease. A Phase 1 study is moving ahead after a clinical hold was lifted.

Option

DNL628, OTV:MAPT

DNL628 is an antisense oligonucleotide therapy for Alzheimer's disease. A Phase 1b study has started dosing.

04 Business segments

One reported business

Discovery and development of therapeutics100%modest

Other reported segments0%flat

Denali reports one operating and reportable segment: discovery and development of therapeutics to defeat degeneration. For the latest disclosed period, revenue was still described as collaboration revenue, with AVLAYAH product sales expected to begin after April 2026 commercial distribution.

05 Risk factors

What could break the thesis

Weak AVLAYAH launch

High impact · Medium odds

Denali is new to commercial sales. AVLAYAH must gain physician adoption, patient starts, and insurer coverage in a small rare disease market. A slow launch would question the value of the first approval and the company's ability to sell its own drugs.

We watchQ2 and Q3 2026 AVLAYAH sales, patient start commentary, and payor coverage updates.

Confirmatory trial failure

High impact · Medium odds

AVLAYAH was approved through the accelerated pathway, which allows earlier approval based on evidence expected to predict benefit. Denali still needs confirmatory evidence. If the COMPASS study does not support benefit, the FDA could require label limits or withdrawal.

We watchUpdates from the Phase 2/3 COMPASS confirmatory study and any FDA comments on post-approval requirements.

Partner exits keep spreading

High impact · Medium odds

Takeda ended the DNL593 collaboration in April 2026. That followed other recent partner exits, including Sanofi's CNS RIPK1 license termination and Takeda's ATV:TREM2 termination. More partner pullbacks would raise the cost for Denali and hurt trust in the pipeline.

We watchBiogen's support for BIIB122, Sanofi's support for eclitasertib, and Denali's plan for DNL593 after rights revert.

Pipeline data disappoints

High impact · Medium odds

Neurodegenerative drug trials fail often. Denali has already seen DNL343 fail in ALS and several partnered programs stop. If BIIB122, DNL126, DNL593, or eclitasertib miss, the company could look too dependent on one rare disease product.

We watchThe Phase 2b LUMA Parkinson's readout, eclitasertib ulcerative colitis data, DNL593 interim data, and DNL126 study completion.

Funding value falls short

Medium impact · Medium odds

The $200 million Royalty Pharma payment and priority review voucher give Denali useful non-dilutive funding. But the company still needs cash to launch AVLAYAH and run multiple trials. If the voucher sale is delayed or priced poorly, Denali may have less flexibility.

We watchTiming and proceeds from any priority review voucher sale, plus quarterly cash burn.

06 Quick answers

In one breath

What does Denali Therapeutics do?

Denali develops drugs for neurodegenerative and lysosomal storage diseases. Its main technology is the Transport Vehicle platform, which is designed to help large drugs cross into the brain.

Is Denali Therapeutics now a commercial company?

Yes. The FDA approved AVLAYAH in March 2026, and commercial distribution began in April 2026. The company still has major research risk because most of its pipeline remains in clinical testing.

Why does AVLAYAH matter so much?

AVLAYAH is Denali's first approved drug and the first real commercial test of its platform. Strong sales and coverage would support the bull case, while a weak launch would make investors question the platform's value.

What is the priority review voucher?

The FDA granted Denali a rare pediatric disease priority review voucher with AVLAYAH approval. Denali can use it for faster FDA review of a future drug application or sell it to another sponsor.